Aller au contenu principal

 Articles scientifiques

The 3<sup>rd</sup> ESTRO-EFOMP core curriculum for medical physics experts in radiotherapy.

Auteurs : Garibaldi C, Essers M, Heijmen B, Bertholet J, Koutsouveli E, Schwarz M, Bert C, Bodale M, Casares-Magaz O, Gerskevitch E, Koniarova I, Korreman S, Lisbona A, Lopez Medina A, Maas A, Moeckli R, Moore M, Petrovic B, Piotrowski T, Poli E, Prezado Y, Reynaert N, Redalen KR, Stylianou Markidou E, Verellen D, Jornet N, Clark CH
Année : 2022
Journal : Radiother Oncol
Volume : 170
Pages : 89-94

PARIS score for evaluation of probability of SARS-CoV-2 infection in cancer patients.

Auteurs : Gueuning C, Ameye L, Loizidou A, Grigoriu B, Meert AP
Année : 2022
Journal : Support Care Cancer
Volume : 30
Pages : 7635-7643

When targeted therapy for cancer leads to ICU admission. RETRO-TARGETICU multicentric study.

Auteurs : Meert AP, Toffart AC, Picard M, Jaubert P, Gibelin A, Bauer P, Mokart D, Van de Louw A, Hatzl S, Moreno-Gonzales G, Rousseau-Bussac G, Bruneel F, Montini L, Moreau AS, Carpentier D, Seguin A, Hemelaar P, Azoulay E, Lemiale V
Année : 2022
Journal : Bull Cancer
Volume : 109
Pages : 916-924

The Road to Dissemination: The Concept of Oligometastases and the Barriers for Widespread Disease.

Auteurs : AlGhamdi H, Dhont J, Krayem M, De Bruyn P, Engels B, Van Gestel D, Van den Begin R
Année : 2022
Journal : Cancers (Basel)
Volume : 14

Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of perilesional sampling.

Auteurs : Noujeim JP, Belahsen Y, Lefebvre Y, Lemort M, Deforche M, Sirtaine N, Martin R, Roumeguère T, Peltier A, Diamand R
Année : 2022
Journal : Prostate Cancer Prostatic Dis

The role of PSMA radioligands in the diagnosis and treatment of prostate carcinoma.

Auteurs : Rodríguez-Fraile M, Tamayo Alonso P, Rosales JJ, de Arcocha-Torres M, Caresia-Aróztegui AP, Cózar-Santiago MP, Orcajo-Rincon J, Simó Perdigó M, Delgado Bolton RC, Artigas C
Année : 2022
Journal : Rev Esp Med Nucl Imagen Mol (Engl Ed)
Volume : 41
Pages : 126-135

Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer.

Auteurs : Chic N, Luen SJ, Nuciforo P, Salgado R, Fumagalli D, Hilbers F, Wang Y, de Azambuja E, Làng I, Di Cosimo S, Saura C, Huober J, Prat A, Loi S
Année : 2022
Journal : J Natl Cancer Inst
Volume : 114(3)
Pages : 467-70

Characteristics and dosimetric impact of intrafraction motion during peripheral lung cancer stereotactic radiotherapy: is a second midpoint cone beam computed tomography of added value?

Auteurs : Benkhaled S, Koshariuk O, Van Esch A, Remouchamps V
Année : 2022
Journal : Rep Pract Oncol Radiother
Volume : 27
Pages : 490-499

Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progressio

Auteurs : Wildiers H, Meyskens T, Marréaud S, Lago LD, Vuylsteke P, Curigliano G, Waters S, Brouwers B, Meulemans B, Sousa B, Poncet C, Brain E
Année : 2022
Journal : Breast
Volume : 64
Pages : 100-111

Cryobiopsy and dye marking guided by electromagnetic navigation bronchoscopy before resection of pulmonary nodule.

Auteurs : Taton O, Sokolow Y, Bondue B, Vandermeeren C, Kuylen MV, Gevenois PA, Remmelink M, Mekinda Ngono Z, Berghmans T, Leduc D
Année : 2022
Journal : Respir Med Res
Volume : 81
Pages : 100911

Magnetic Resonance Imaging-based T-staging to Predict Biochemical Recurrence after Radical Prostatectomy: A Step Towards the iTNM Classification.

Auteurs : Baboudjian M, Gondran-Tellier B, Touzani A, Martini A, Diamand R, Roche JB, Lacetera V, Beauval JB, Roumeguère T, Simone G, Benamran D, Fourcade A, Fiard G, van den Bergh RCN, Peltier A, Ploussard G
Année : 2022
Journal : Eur Urol Oncol

Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.

Auteurs : Bobin A, Kyheng M, Guidez S, Gruchet-Merouze C, Richez V, Duhamel A, Karlin L, Kolb B, Tiab M, Araujo C, Meuleman N, Malfuson JV, Bourquard P, Lenain P, Perrot A, Roussel M, Jaccard A, Petillon MO, Belhadj-Merzoug K, Chretien ML, Fontan J, Rodon P, Schmitt A, Offner F, Voillat L, Cereja S, Kuhnowski F, Rigaudeau S, Decaux O, Humbrecht-Kraut C, Frayfer J, Fitoussi O, Roos-Weil D, Eisenmann JC, Dorvaux V, Voog EG, Moreau P, Avet-Loiseau H, Hulin C, Facon T, Leleu X
Année : 2022
Journal : Leukemia
Volume : 36
Pages : 881-884

Temper the Specialist Nurses Heterogeneity in the Interest of Quality Practice and Mobility-18 EU Countries Study.

Auteurs : Decock N, Friganovic A, Kurtovic B, Oomen B, Crombez P, Willems C
Année : 2022
Journal : Healthcare (Basel)
Volume : 10

Suburethral implantation of autologous regenerative cells for female stress urinary incontinence management: Results of a pilot study.

Auteurs : Maene A, Deniz G, Bouland C, Lagneaux L, Philippart P, Buxant F
Année : 2022
Journal : Eur J Obstet Gynecol Reprod Biol
Volume : 278
Pages : 38-44

An Atypical Behavior of Metastatic Lung Disease in a Young Woman With Osteosarcoma: A Case Report.

Auteurs : Acquisto A, Duran Derijckere I, De Angelis R
Année : 2022
Journal : Cureus
Volume : 14
Pages : e21589

What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.

Auteurs : Pizzamiglio S, Cosentino G, Ciniselli CM, De Cecco L, Cataldo A, Plantamura I, Triulzi T, El-Abed S, Wang Y, Bajji M, Nuciforo P, Huober J, Ellard SL, Rimm DL, Gombos A, Daidone MG, Verderio P, Tagliabue E, Di Cosimo S, Iorio MV
Année : 2022
Journal : Cancer Med
Volume : 11
Pages : 332-339

Heterogeneity of dose distribution in normal tissues in case of radiopharmaceutical therapy with alpha-emitting radionuclides.

Auteurs : Li WB, Bouvier-Capely C, Saldarriaga Vargas C, Andersson M, Madas B
Année : 2022
Journal : Radiat Environ Biophys
Volume : 61
Pages : 579-596

Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study.

Auteurs : Nader-Marta G, Debien V, Eiger D, Tsourti Z, Caparica R, Kassapian M, Napoleone S, Hultsch S, Korde L, Wang Y, Chumsri S, Pritchard KI, Untch M, Bellet-Ezquerra M, Dornelles Rosa D, Moreno-Aspitia A, Piccart M, Dafni U, de Azambuja E
Année : 2022
Journal : Br J Cancer
Volume : 127
Pages : 1799-1807

Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.

Auteurs : Schuster M, Zijlstra J, Casasnovas RO, Vermaat JSP, Kalakonda N, Goy A, Choquet S, Neste EVD, Hill B, Thieblemont C, Cavallo F, De la Cruz F, Kuruvilla J, Hamad N, Jaeger U, Caimi P, Gurion R, Warzocha K, Bakhshi S, Sancho JM, Follows G, Egyed M, Offner F, Vassilakopoulos T, Samal P, Ku M, Ma X, Corona K, Chamoun K, Shah J, Shacham S, Kauffman MG, Canales M, Maerevoet M
Année : 2022
Journal : Clin Lymphoma Myeloma Leuk
Volume : 22
Pages : 483-494

Oncological outcomes of radical prostatectomy in very high-risk patients according to STAMPEDE criteria: does local treatment alone still have a place in the era of intensified systemic therapies?

Auteurs : Baboudjian M, Touzani A, Martini A, Diamand R, Roche JB, Lacetera V, Beauval JB, Gondran-Tellier B, Roumeguère T, Simone G, Windisch O, Benamran D, Fourcade A, Fiard G, Van Den Bergh RC, Peltier A, Ploussard G
Année : 2022
Journal : Minerva Urol Nephrol